Precigen, Inc. (NASDAQ:PGEN - Get Free Report) shares saw an uptick in trading volume on Wednesday . 1,162,796 shares changed hands during trading, a decline of 18% from the previous session's volume of 1,424,528 shares.The stock last traded at $1.89 and had previously closed at $1.70.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on PGEN. HC Wainwright restated a "buy" rating and set a $6.00 target price on shares of Precigen in a report on Thursday, March 20th. Cantor Fitzgerald restated an "overweight" rating on shares of Precigen in a report on Thursday, May 15th. Wall Street Zen cut Precigen from a "hold" rating to a "sell" rating in a report on Saturday, May 24th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $6.00 price target on shares of Precigen in a research report on Thursday, June 12th.
View Our Latest Research Report on Precigen
Precigen Stock Performance
The stock has a 50-day moving average of $1.45 and a 200-day moving average of $1.46. The firm has a market cap of $563.79 million, a price-to-earnings ratio of -3.41 and a beta of 1.78.
Precigen (NASDAQ:PGEN - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The business had revenue of $1.34 million for the quarter, compared to analyst estimates of $0.50 million. Precigen had a negative return on equity of 279.20% and a negative net margin of 3,728.87%. Sell-side analysts predict that Precigen, Inc. will post -0.32 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Envestnet Asset Management Inc. increased its holdings in shares of Precigen by 29.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 5,915 shares during the last quarter. Invesco Ltd. lifted its position in shares of Precigen by 14.6% during the 4th quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 6,040 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Precigen by 12.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company's stock valued at $122,000 after acquiring an additional 9,043 shares during the period. ProShare Advisors LLC lifted its position in shares of Precigen by 26.6% during the 4th quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock valued at $58,000 after acquiring an additional 10,900 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in shares of Precigen by 12.0% during the 4th quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company's stock worth $128,000 after buying an additional 12,285 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors.
Precigen Company Profile
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Further Reading
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.